Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

Who needs cerebrospinal biomarkers? A national survey in clinical practice.

Troussière AC, Wallon D, Mouton-Liger F, Yatimi R, Robert P, Hugon J, Hannequin D, Pasquier F, Paquet C.

J Alzheimers Dis. 2014;40(4):857-61. doi: 10.3233/JAD-132672.

PMID:
24577469
[PubMed - in process]
2.

The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations.

Gooblar J, Carpenter BD, Coats MA, Morris JC, Snider BJ.

Alzheimers Dement. 2014 Jul 8. pii: S1552-5260(14)00645-1. doi: 10.1016/j.jalz.2014.04.517. [Epub ahead of print]

PMID:
25022536
[PubMed - as supplied by publisher]
3.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
[PubMed - indexed for MEDLINE]
4.

Biomarkers in Alzheimer's disease: a review.

Chintamaneni M, Bhaskar M.

ISRN Pharmacol. 2012;2012:984786. doi: 10.5402/2012/984786. Epub 2012 Jun 28.

PMID:
22811931
[PubMed]
Free PMC Article
5.

Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study.

Mouton-Liger F, Wallon D, Troussière AC, Yatimi R, Dumurgier J, Magnin E, de la Sayette V, Duron E, Philippi N, Beaufils E, Gabelle A, Croisile B, Robert P, Pasquier F, Hannequin D, Hugon J, Paquet C.

J Neurol. 2014 Jan;261(1):144-51. doi: 10.1007/s00415-013-7160-3. Epub 2013 Oct 27.

PMID:
24162039
[PubMed - in process]
6.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
[PubMed - indexed for MEDLINE]
7.

Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease.

Nazco CV, Pérez LP, Molinuevo JL, Mar J, Castilla I, Aguilar PS.

J Alzheimers Dis. 2014 Jun 10. [Epub ahead of print]

PMID:
24916543
[PubMed - as supplied by publisher]
8.

Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study.

Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc'h K, Schraen S, Buée L, Pasquier F, Hugon J, Touchon J, Lehmann S.

J Alzheimers Dis. 2013;34(1):297-305. doi: 10.3233/JAD-121549.

PMID:
23186986
[PubMed - indexed for MEDLINE]
9.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
[PubMed - indexed for MEDLINE]
10.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
[PubMed - indexed for MEDLINE]
11.

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H.

Alzheimers Dement. 2014 May 2. pii: S1552-5260(14)00066-1. doi: 10.1016/j.jalz.2014.02.004. [Epub ahead of print] Review.

PMID:
24795085
[PubMed - as supplied by publisher]
12.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. Review.

PMID:
23489287
[PubMed - in process]
13.

Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Jahn H, Wittke S, Zürbig P, Raedler TJ, Arlt S, Kellmann M, Mullen W, Eichenlaub M, Mischak H, Wiedemann K.

PLoS One. 2011;6(10):e26540. doi: 10.1371/journal.pone.0026540. Epub 2011 Oct 26.

PMID:
22046305
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment.

Balasa M, Sánchez-Valle R, Antonell A, Bosch B, Olives J, Rami L, Castellví M, Molinuevo JL, Lladó A.

J Alzheimers Dis. 2014;40(4):919-27. doi: 10.3233/JAD-132195.

PMID:
24577466
[PubMed - in process]
15.

The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.

Engelborghs S, Le Bastard N.

J Neurol Sci. 2012 Nov 15;322(1-2):197-9. doi: 10.1016/j.jns.2012.08.003. Epub 2012 Sep 2.

PMID:
22947896
[PubMed - indexed for MEDLINE]
16.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080
[PubMed - indexed for MEDLINE]
17.

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports.

Slats D, Spies PE, Sjögren MJ, Verhey FR, Verbeek MM, Olde Rikkert MG.

Case Rep Neurol. 2010 Feb 24;2(1):5-11.

PMID:
20689628
[PubMed]
Free PMC Article
18.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.

Arch Neurol. 2012 Nov;69(11):1445-52.

PMID:
22925882
[PubMed - indexed for MEDLINE]
19.

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.

Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O.

PLoS One. 2012;7(6):e38639. doi: 10.1371/journal.pone.0038639. Epub 2012 Jun 22.

PMID:
22761691
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Analysis of combined CSF biomarkers in AD diagnosis.

De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, Bolner A, Perini F.

Clin Lab. 2014;60(4):629-34.

PMID:
24779297
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk